The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
about
Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-MycDrug Discovery Targeting Bromodomain-Containing Protein 4.Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.AR Signaling in Breast Cancer.High-Throughput Spheroid Screens Using Volume, Resazurin Reduction, and Acid Phosphatase Activity.Hypoxia-induced apoptosis of mouse spermatocytes is mediated by HIF-1α through a death receptor pathway and a mitochondrial pathway.Bromodomain inhibitors and cancer therapy: From structures to applications.BET Bromodomain Proteins as Cancer Therapeutic Targets.Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.Small molecule selectively suppresses MYC transcription in cancer cells.BET inhibitors as novel therapeutic agents in breast cancer.Targeting bromodomain and extraterminal proteins in breast cancer.Identification of differentially expressed genes regulated by molecular signature in breast cancer-associated fibroblasts by bioinformatics analysis.Epigenetic regulators: multifunctional proteins modulating hypoxia-inducible factor-α protein stability and activity.Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.The hypoxia-responsive lncRNA NDRG-OT1 promotes NDRG1 degradation via ubiquitin-mediated proteolysis in breast cancer cells.Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease.Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors
P2860
Q28559676-72852EB1-D8F7-4527-A9F6-9CFB342C1430Q30352390-9F4C33D4-D0BF-49DD-A828-D641C3B76C57Q33842529-C67F2EC5-19B6-4773-B2C3-15D398B39C06Q37721492-063B51CA-DB7F-4D73-8D21-7D74FD5A3A79Q38805675-443CD337-E2D5-44CA-A1B1-B36B4DCBB20AQ38818875-15CFCF2D-A466-4B70-81B7-197C8BAC0C92Q39027056-24581DE4-8C73-4437-B49B-584AEE763183Q39071349-9866BC23-F713-42E5-BA3E-0E1C5399F1CBQ40053251-6DBF420E-0F2D-4DC8-B546-044BFEE18B0DQ41677833-47B20BC7-3A55-41BB-9D8A-07DEE42C5264Q42378528-F511E02C-0F6F-42C3-BB87-DAFB8E000E7EQ47385983-70769F84-C6E6-4C5F-9694-AC56632EE736Q47612265-B8598A61-79D5-45AB-9557-2B965E741ED0Q47651765-36739426-0C68-4579-A299-7D567754B77DQ47953349-B26D8C45-C3CD-4663-BF90-B9291687CD2AQ48551091-73299D37-0BC0-4DDC-82AB-80EA83658655Q52657089-CDB680E3-160C-4DB1-BCC0-C0945382220EQ55087013-52FB2B14-8C3C-472E-97CD-1B9DF1BACA00Q56892267-6C07F4D8-8341-421B-BD5B-50D3260CFC0F
P2860
The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The BET inhibitor JQ1 selectiv ...... triple negative breast cancer.
@en
The BET inhibitor JQ1 selectiv ...... triple negative breast cancer.
@nl
type
label
The BET inhibitor JQ1 selectiv ...... triple negative breast cancer.
@en
The BET inhibitor JQ1 selectiv ...... triple negative breast cancer.
@nl
prefLabel
The BET inhibitor JQ1 selectiv ...... triple negative breast cancer.
@en
The BET inhibitor JQ1 selectiv ...... triple negative breast cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
The BET inhibitor JQ1 selectiv ...... triple negative breast cancer.
@en
P2093
L L da Motta
S Wigfield
P2860
P2888
P304
P356
10.1038/ONC.2016.184
P407
P577
2016-06-13T00:00:00Z